HOME >> BIOLOGY >> NEWS
Stanford explores new avenue for brain injury, paralysis research

STANFORD, Calif. - The central nervous system, made up of the brain and spinal cord, never forgets a slight. Somehow, nerve cells lose the ability to regenerate: witness actor Christopher Reeve's paralysis after his horse threw him at a jump. To find a cure for such injuries, scientists must understand why nerve cells lose the ability to grow back. They know that these cells - called neurons - stop regenerating because a signal tells them to slow down during development. The problem is, scientists haven't known much about that signal.

Now, a team of Stanford University Medical Center researchers have identified the mechanism and some key cells involved in controlling regeneration. It turns out that the signal to slow down doesn't come from the neurons themselves, but from an outside source. The signal's effects appear to be permanent. The findings, published in the June 7 issue of Science, outline what may be a new avenue to explore in the search for brain-damage and paralysis treatments, the researchers say.

Messages move through the average neuron like tributaries flowing into a river. The tributaries are called dendrites, and they flow into the axon, the river itself, which in turn can share messages with dendrites further downstream.

When Reeve fell from his horse, neurons that weren't killed outright may have had their axons chopped in half, disconnecting them from the network. "This is the core problem in neural degenerative diseases, especially things like spinal cord injury. Axons that get cut don't grow past the site of the injury back to normal connections in the brain," said Jeffrey Goldberg, lead author of the paper and senior graduate student in the lab of Ben A. Barres, MD, PhD, associate professor of neurobiology and developmental biology. "When a person is paralyzed, that's permanent," he said.

Left to their own devices, neurons in the central nervous system grow back so slowly that they o
'"/>

Contact: Amy Adams
amyadams@stanford.edu
650-723-3900
Stanford University Medical Center
6-Jun-2002


Page: 1 2 3

Related biology news :

1. Tiny molecules have big potential as cancer drugs, Stanford researcher believes
2. Stanford researchers findings may shed light on common, deadly birth defect
3. Leukemia stem cells identified by Stanford researchers
4. New view of leukemia cells identifies best treatment options, Stanford researchers say
5. Confidentiality of genetic databases questioned by Stanford researchers
6. Stanford researchers go from heaven to Earth in lifeguard test
7. Transplant rejection averted by simple light exposure in Stanford animal study
8. Fat cells heal skull defects in mice, Stanford research shows
9. Gene-based screen sorts cancer cases, say Stanford researchers
10. Elusive but ubiquitous microbe fingered as gum disease culprit in Stanford study
11. Sticklebacks reveal secrets to evolutionary change in Stanford study

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Stanford explores new avenue for brain injury paralysis research

(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Card Alliance and the EMV Migration Forum.  ... Card Alliance Latin America (SCALA) Chapter provides NXT-ID, Inc. ... leaders promoting adoption of smart card technology. ...
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
(Date:9/2/2015)... , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... to their offering. This report follows ... characteristic that can be objectively measured and evaluated ... processes as well as pharmacological responses to a ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., ... in the multicenter Phase 2 clinical trial of ... treatment of recurrent subfoveal choroidal neovascularization secondary to ... a unique vascular endothelial growth factor (VEGF) receptor ... "This landmark proof-of-concept study will evaluate ...
(Date:9/2/2015)... , September 2, 2015 BiondVax ... of the National Institute of Allergy and Infectious Diseases (NIAID), ... the Department of Health and Human Services (HHS), to launch ... the United States in the 2015-16 timeframe. ... vaccine candidate, Multimeric-001 (M-001), as a primer vaccine, which would ...
(Date:9/2/2015)... ... September 02, 2015 , ... The ... creating professional commercial video content, to analysis of athletic performance. Producing high-resolution ... go by too quickly to process with the naked eye. , Slow ...
Breaking Biology Technology:Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3
Cached News: